Lyell Immunopharma's IMPT-314 Shows Promise in Phase 1-2 Trial for Large B-Cell Lymphoma
Key Insights
Lyell Immunopharma is presenting initial Phase 1-2 clinical data for IMPT-314, a dual-targeting CAR T-cell therapy, at the ASH Annual Meeting.
IMPT-314 targets both CD19 (search) and CD20 (search) and is being developed for aggressive B-cell non-Hodgkin’s lymphoma (search) patients.
The FDA has granted Fast Track Designation to IMPT-314 for relapsed/refractory aggressive B-cell lymphoma, potentially expediting its development.
Lyell Immunopharma is set to present initial clinical data from its Phase 1-2 study of IMPT-314, a dual-targeting CD19 (search)/CD20 (search) CAR T-cell therapy, at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The presentation by Sarah M. Larson, M.D., from UCLA, will highlight the potential of IMPT-314 in treating patients with aggressive B-cell non-Hodgkin’s lymphoma (search).
IMPT-314: A Novel Approach to B-Cell Lymphoma
IMPT-314 is an autologous bispecific CAR T-cell product engineered to target both CD19 (search) and CD20 (search), two proteins expressed on B-cells. This dual-targeting approach aims to improve the depth and durability of response in patients with large B-cell lymphoma (search) (LBCL). The therapy utilizes enriched naive and central memory T cells, which are believed to enhance long-term efficacy and reduce T-cell exhaustion.
Fast Track Designation
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to IMPT-314 for the treatment of relapsed/refractory aggressive B-cell lymphoma. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.
ASH Presentation Details
The poster presentation, titled "First Results of IMPT-314, an Autologous Bispecific CD19 (search)/CD20 (search) Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)," will take place on Monday, December 9, 2024, from 6:00 PM to 8:00 PM in Halls G-H of the San Diego Convention Center. The presentation will provide an overview of the early clinical trial results, including safety and efficacy data.
Lyell is focused on advancing next-generation CAR T-cell therapies for solid tumors and hematologic malignancies. Their technology is designed to generate T cells that resist exhaustion and maintain stemness, potentially leading to durable tumor cytotoxicity and long-lasting clinical responses.